TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Delcath Systems ( (DCTH) ) has provided an update.
On November 19, 2025, Delcath Systems, Inc.’s board of directors approved a share repurchase program, allowing the company to buy back up to $25 million of its common stock, contingent on market conditions. This strategic move could potentially enhance shareholder value and indicates the company’s confidence in its financial position and future prospects.
The most recent analyst rating on (DCTH) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.
Spark’s Take on DCTH Stock
According to Spark, TipRanks’ AI Analyst, DCTH is a Neutral.
Delcath Systems’ overall score is driven by strong financial performance and promising clinical trial results. However, the stock faces challenges with bearish technical indicators and a high P/E ratio suggesting overvaluation. The earnings call provided a mixed outlook with both positive developments and notable challenges.
To see Spark’s full report on DCTH stock, click here.
More about Delcath Systems
Average Trading Volume: 829,161
Technical Sentiment Signal: Sell
Current Market Cap: $300.5M
Find detailed analytics on DCTH stock on TipRanks’ Stock Analysis page.